Azamat Abdimukhtar

Azamat Abdimukhtar

Auto-generated profile, based on publicly available information

Azamat Abdimukhtar

Research Institute for Biological Safety Problems, 25/1, Korday District, Gvardeyskiy 080409, Zhambyl Region, Kazakhstan

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2025 in Antibiotics
Verified
Journal Article
Open access
PDF file
BYBolat Yespembetov
Bolat Yespembetov
ZKZhumagul Kirkimbayeva
Zhumagul Kirkimbayeva
AAAkbope Abdykalyk
Akbope Abdykalyk
AAAssel Akhmetova
Assel Akhmetova
ASAlexandr Shevtsov
Alexandr Shevtsov
ATAlinur Toleukhan
Alinur Toleukhan
Background/Objectives: Salmonella enterica is a major cause of foodborne infection globally, with poultry acting as an important reservoir. However, data from Central Asia remain limited. This study provides preliminary phenotypic and genomic characterization of S. enterica isolates recovered from poultry farms in southern Kazakhstan, focusing on antimicrobial resistance (AMR), serotypes/sequence types and phylogenetic relationships. Methods: In October 2024, 335 poultry and environmental samples were collected from three regions of southern Kazakhstan using a cross-sectional, detection-focused sampling strategy. Isolation of Salmonella enterica followed enrichment and selective culturing, with confirmation by biochemical assays, slide agglutination serology and real-time PCR. Antimicrobial susceptibility testing was performed using the Kirby-Bauer disk diffusion method and interpreted according to CLSI veterinary breakpoints (VET01/VET08) and CLSI M100 where veterinary criteria were unavailable. Whole-genome sequencing (Illumina) was used for in silico serotyping, MLST, AMR gene detection, plasmid replicon typing and SNP-based phylogenetic reconstruction. Results: Nine S. enterica isolates were confirmed (overall yield 2.7%; 9/335), comprising S. Enteritidis (ST11; n = 4), S. Infantis (ST32; n = 3) and ST68 (n = 2; Choleraesuis/Paratyphi C lineage). All isolates were resistant to ciprofloxacin, and most displayed resistance to ampicillin, gentamicin and trimethoprim-sulfamethoxazole. Plasmid-associated AMR determinants, including blaTEM-116, tet(A), sul1 and dfrA14, were frequently identified on IncF-type replicons. Phylogenetic analysis revealed that the isolates clustered with previously described Eurasian poultry-associated lineages. Conclusions: In this small, exploratory sample from poultry farms in southern Kazakhstan, all recovered S. enterica isolates were multidrug-resistant, with universal fluoroquinolone resistance and frequent plasmid-borne AMR genes. These preliminary findings provide baseline genomic evidence and highlight the need for broader, harmonized AMR surveillance in the regional poultry sector.

22 May 2026 in Pathogens
Verified
Journal Article
Open access
PDF file
NSNazym Syrym
Nazym Syrym
BYBolat Yespembetov
Bolat Yespembetov
SKSabit Kokanov
Sabit Kokanov
ANAziz Nakhanov
Aziz Nakhanov
Yerbol Ye BulatovYerbol Ye Bulatov
Yerbol Ye Bulatov
AAAkbope Abdykalyk
Akbope Abdykalyk
Bacterial sexually transmitted and sexually associated infections remain a major global health concern, increasingly complicated by antimicrobial resistance and the limited effectiveness of existing therapies. In this context, bacteriophage-based and phage-derived approaches have re-emerged as potential alternative antibacterial strategies. This narrative review examines their applicability across key bacterial pathogens associated with sexually transmitted infections, including Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, Treponema pallidum and biofilm-associated bacterial vaginosis, with a particular focus on pathogen-specific biological barriers. Available evidence indicates that the success of phage-based interventions is strongly dependent on factors such as intracellular localisation, structural characteristics of the bacterial envelope and the presence of polymicrobial biofilms. While phage-derived platforms, including endolysins, depolymerases and engineered phages, demonstrate antibacterial activity in experimental settings, their effectiveness is uneven across different pathogens. Biofilm-associated infections appear more accessible to these approaches, whereas intracellular and structurally atypical bacteria are currently considered more challenging targets based on available mechanistic and experimental evidence. These observations highlight the need for pathogen-specific engineering strategies and delivery systems. Overall, phage-based therapeutics in this field should be considered within a framework that integrates biological constraints with targeted antimicrobial design.

10 April 2026 in Biosafety and Biotechnology
Verified
Journal Article
Closed access
BYBolat Yespembetov
Bolat Yespembetov
SAS. Alpysbayeva
S. Alpysbayeva
MSM. Sarmykova
M. Sarmykova
AKAslan Kerimbaev
Aslan Kerimbaev
AAA. Abdimukhtar
A. Abdimukhtar
AAAkbope Abdykalyk
Akbope Abdykalyk
The present study evaluated the local and systemic tolerability of vaccine formulation components in the absence of antigen following intranasal and sublingual administration in outbred white laboratory mice. The investigated substances included excipients of the vaccine formulation mannitol and gelatin at various concentrations as well as phosphate-buffered saline and water for injection, which are used as technological components during the development of vaccine candidates. The control group consisted of intact animals. Tolerability was assessed over a 10-day observation period based on clinical condition, body weight dynamics, and key blood biochemical parameters. All tested substances demonstrated good tolerability: no clinically significant local or systemic reactions were observed, and the evaluated biochemical parameters remained within reference ranges. Based on the overall assessment, mannitol at a concentration of 5% and gelatin at 0.5% were identified as optimal. The obtained results indicate the safety of the investigated excipients and technological components and confirm their suitability for use at the preclinical stage of development of vector-based anti-brucellosis vaccine candidates utilizing an influenza virus platform.

7 January 2026 in Veterinary Medicine and Science
Verified
Journal Article
Open access
SASabira E. Alpysbayeva
Sabira E. Alpysbayeva
AAAkbope Abdykalyk
Akbope Abdykalyk
KTKali Tileukhanov
Kali Tileukhanov
AAAzamat R. Abdimukhtar
Azamat R. Abdimukhtar
ATAlinur Toleukhan
Alinur Toleukhan
BYBolat Yespembetov
Bolat Yespembetov
Background: Epizootic lymphangitis (EEL), caused by Histoplasma capsulatum var. farciminosum (HCF), is a neglected equine fungal disease lacking effective vaccines. The newly developed inactivated ‘8ZH’ vaccine requires safety validation in the target species. Objectives: To evaluate the biochemical, haematological and clinical safety of the inactivated HCF ‘8ZH’ vaccine in foals. Methods: A controlled, single‐blinded study was conducted on 30 clinically healthy foals (4–6 months), randomized into vaccinated (n = 15) and control (n = 15) groups. Vaccinated animals received a 5 mL intramuscular dose (10 mg antigen, MONTANIDE GEL 01 PR adjuvant) on Day 0 and a booster on Day 21. Clinical observations (temperature, appetite, behaviour, injection site) were recorded daily. Blood was collected at baseline and on Days 7, 14, 21, 35 and 42 for biochemical, haematological and acute‐phase protein analysis. Data were analysed using repeated measures ANOVA. Results: No severe or adverse reactions were observed. Mild, transient injection‐site swelling (< 4 cm) occurred in three vaccinated foals and resolved spontaneously. All animals maintained normal temperature and appetite. AST showed a transient increase on Day 14 ( p = 0.04); WBC also rose ( p = 0.03), indicating a typical immune response. Other parameters, including ALT, GGT, creatinine, total bilirubin and acute‐phase proteins (SAA, fibrinogen, haptoglobin), remained within physiological limits. No statistically significant long‐term deviations or toxic effects were noted. Conclusions: The inactivated HCF ‘8ZH’ vaccine demonstrated a favourable safety profile in foals. These results support its continued development for use in EEL prevention programs.

16 September 2024 in Biosafety and Biotechnology
Verified
Journal Article
Open access
PDF file
NZN. N. Zinina
N. N. Zinina
BYBolat Yespembetov
Bolat Yespembetov
NSNazym Syrym
Nazym Syrym
SAS. E. Alpysbaeva
S. E. Alpysbaeva
MSM. K. Sarmykova
M. K. Sarmykova
ЕСЕ. Б. Серикбай
Е. Б. Серикбай
When testing anti-brucellosis vaccines, an important role is played by studying the infecting dose of control strains. To restore the virulent properties of the control strains Brucella melitensis 16 M and Brucella abortus 544, it is necessary to carry out multiple successive passages in different doses (starting from 1,000,000 colony-forming units, CFU/cm3 to 5 CFU/cm3), through the body of sensitive laboratory animals. In this case, for experimental work, we took 54 heads of guinea pigs (males) weighing 350-380 g, from which we created 9 groups of 6 heads each. The article reflects the progress and results of research into determining the minimum fixing infectious dose of the control reference strains Brucella melitensis 16 M and Brucella abortus 544.Based on the results of the studies, the minimum infectious dose (5 CFU) of Brucella after the ninth passage, which causes the generalized form of brucellosis, was determined. Spent virulent fixing doses (5 CFU/cm3) strains of Brucella melitensis 16 M and Brucella abortus 544 can be used for control infection when setting up various experiments to determine and evaluate the immunogenicity of anti-brucellosis vaccines and chemoprophylaxis.

29 September 2026 in BioTech
Verified
Journal Article
Open access
PDF file
MSMakhpal Sarmykova
Makhpal Sarmykova
AAAkbope Abdykalyk
Akbope Abdykalyk
NSNazym Syrym
Nazym Syrym
BYBolat Yespembetov
Bolat Yespembetov
AAAktoty Anarbekova
Aktoty Anarbekova
SNSergazy Nurabayev
Sergazy Nurabayev
Drug-resistant Klebsiella pneumoniae is a serious clinical problem, and bacteriophages are being investigated again as antibacterial agents. This study describes the phenotypic characterization and a preliminary in vivo evaluation of vB_Kpn_NIIPB-V0006, a bacteriophage isolated locally on a drug-resistant clinical K. pneumoniae strain. The genome of the phage was not sequenced. It has therefore not been screened for lysogeny-associated, toxin, virulence or antimicrobial resistance genes, and the results below describe what the phage does, not whether it is suitable for therapy. We assessed plaque morphology, specific lytic activity, titer, host range on a limited non-target panel, particle morphology, adsorption, one-step growth, chloroform exposure, the frequency of phage-resistant host variants, endotoxin reduction, short-term safety in mice and antibacterial effect in guinea pigs. The phage lysed the target strain, with an Appelman activity of 10−8 and a titer of 1.7 × 1011 PFU/mL. Processing with 1-octanol lowered endotoxin content from 1200 to 12 EU/mL and preserved 80% of infective activity. Mice given the preparation intraperitoneally showed no mortality and no visible acute toxicity over 14 days. In guinea pigs with systemic K. pneumoniae infection, survival was the primary outcome: 0.5 mL three times daily gave 6/6 survivors against 1/6 in untreated controls (p = 0.015). Splenic bacterial burden, a secondary outcome, was also lower in that group (2.64 against 4.41 log10 CFU/g). Two features of the design bias this second comparison in favor of treatment, since survivors and non-survivors were sampled at different times, and phage being carried over into the plating step is likely to have lowered colony counts. The 1.77 log10 difference should therefore be read as an upper bound. The phage merits further study, but whole-genome sequencing, confirmation of the host species, host-range testing against diverse clinical isolates and a controlled comparison with antibiotic treatment are all needed before any therapeutic claim can be made.